cabazitaxel (Jevtana) -

cabazitaxel (Jevtana)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Renal and urologic disorders
Summary
Cabazitaxel (in combination with prednisone or prednisolone) for hormone refractory metastatic prostate cancer previously treated with docetaxel is not recommended for use within NHS Scotland. The manufacturer did not present a sufficiently robust economic case.
UKMi comment
NICE TA391 recommends Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel only if:

• The person has an eastern cooperative oncology group (ECOG) performance status of 0 or 1

• The person has had 225 mg/m2 or more of docetaxel

• Treatment with cabazitaxel is stopped when the disease progresses or after a maximum of 10 cycles (whichever happens first)

• NHS trusts purchase cabazitaxel in pre prepared intravenous infusion bags, not in vials
Related links: NICE TA 391